Navigation Links
Rhythm Names Keith M. Gottesdiener Chief Executive Officer
Date:11/9/2011

BOSTON, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today the appointment of Keith M. Gottesdiener, MD, as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from Merck & Co., Inc., where he served as Vice President and Late-Stage Therapeutic Group Leader, with responsibility for pivotal trials of Merck's products in all therapeutic areas, and previously as head of early-stage clinical development programs.

"The Rhythm clinical candidates are peptides with some important advantages over small molecules for targeting complex pathways that regulate body weight and gastrointestinal function," said Dr. Gottesdiener. "I am excited to join the Rhythm team to develop this pipeline of peptide therapeutics that have real potential to become breakthrough drugs for obesity, diabetes, and GI metabolic disorders."

Over a 16-year career at Merck, Dr. Gottesdiener was responsible for more than 40 major clinical programs and products, including the approval of Gardasil™ (HPV vaccine) and the more recent FDA approval of Victrelis™ (HCV protease inhibitor). Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania, and he completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs.

"Keith's experience and accomplishments developing innovative, best-in-class drugs—including the diabetes blockbuster, Januvia™—are exceptional," said Bart Henderson, President and co-founder of Rhythm. "He comes to Rhythm at an ideal time, as we advance clinical development of RM-131 for the treatment of diabetic gastroparesis and RM-493 for obesity and diabetes."

"Keith's deep understanding of the clinical development process will greatly enhance Rhythm's novel approach to molecular mechanisms of body weight regulation," said Lou Tartaglia, Ph.D., Rhythm's Chief Scientific Officer and a Partner at Third Rock Ventures. "We are very excited to have attracted such world-class talent to join us in building a great company in the metabolic field."

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Differing structures underlie differing brain rhythms in healthy and ill
2. Dangerous arrhythmia analyzed in a heartbeat
3. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
4. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
5. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
6. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
7. Guam rhino beetles got rhythm
8. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. OXIS International Names David Saloff as Chief Executive Officer
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... , June 22, 2016  According to ... next generation sequencing (NGS) market include significant efforts ... smaller sequencers.  More accessible and affordable sequencers, say ... growing demand for consumables including sample prep materials.  ... Market for Sample Preparation for Next Generation Sequencing ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, the ... current participant in the Phase 1 Ventures program, is leveraging regional and federal ... Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging using ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
(Date:6/22/2016)... , June 22, 2016  Mesa Biotech ... developed a testing platform designed specifically for point-of-care ... of their scientific advisory board (SAB). Approved by ... the SAB is chartered to advise on the ... assay platform. Led by Dr. Steve Young ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):